Combination products continue to be on the rise, from the innovation of novel medicines and greater demand for injectable home and self-administration. Qualification will depend upon the regulatory jurisdiction with reference to the product’s primary mode of action; to facilitate this, a consult or collaborative review process involving different centers within the FDA may be necessary